FDA
-
-
-
-
-
-
-
FDA expands Casgevy approval to children as young as 2
-
-
-
-
-
-
-
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
-
-
-
-
-
-
-
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
-
-
-
-
-
-
-
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
-
-
-
-
-
-
-
Vertex reports promising phase 1/2 data for povetacicept kidney drug
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
Vertex (VRTX) PT Lowered to $530 at BMO Capital
-
327,806 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

